Liraglutide vs Tirzepatide
Saxenda, VictozavsMounjaro, Zepbound
Liraglutide (sold as Saxenda and Victoza) and tirzepatide (sold as Mounjaro and Zepbound) are both injectable therapies for type 2 diabetes and weight management; liraglutide is a GLP-1 receptor agonist administered once daily, while tirzepatide is a dual GIP and GLP-1 receptor agonist administered once weekly.
Vial summary · compiled from public records
At a glance
Liraglutide
Sold as Saxenda, Victoza
- Category
- Metabolic
- FDA / legal status
- FDA Approved
- Route
- Subcutaneous
Tirzepatide
Sold as Mounjaro, Zepbound
- Category
- Weight Loss
- FDA / legal status
- Restricted
- Route
- Subcutaneous
Side by side
| Field | Liraglutide | Tirzepatide |
|---|---|---|
| Category | Metabolic | Weight Loss |
| Brand names | Saxenda, Victoza | Mounjaro, Zepbound |
| FDA / legal status | FDA Approved | Restricted |
| Evidence tier | Clinical Trials | FDA Approved |
| Administration route | Subcutaneous | Subcutaneous |
| Compounding access | FDA-approved product, dispensed by prescription | Restricted |
| Providers on Vial | 0 listed | 23 listed |
| Typical price band | Varies by provider | $ to $$ |
Verified providers offering each
Ranked by Vial Score, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.
Liraglutide0 top providers
No surfaceable providers currently list Liraglutide on Vial.
See all 0 providers offering liraglutide →About each compound
About Liraglutide
Liraglutide is a once-daily GLP-1 receptor agonist marketed as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first GLP-1 agents to demonstrate meaningful weight loss in clinical trials, producing 5–8% body weight reduction on average. Though largely superseded by weekly agents, it remains a clinically validated option. Compounded liraglutide is available through select pharmacies.
About Tirzepatide
A synthetic dual agonist peptide, tirzepatide activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. The compound produces significant improvements in glycemic control and body weight reduction. Primary clinical applications include treatment of type 2 diabetes mellitus and chronic weight management in adults with obesity.
Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.
Related compound comparisons
Other comparisons in the same category.